Actinic keratosis : where do we stand and where is the future going to take us?
Introduction: Actinic keratosis (AK) is a chronic disease which is mainly located across areas of sun-exposed skin. Clinical and subclinical lesions coexist across a large area resulting in a field cancerization. As these lesions have the potential to transform into invasive squamous cell carcinoma (iSCC), treatment is crucial. With global prevalence increasing, AK is expected to be the most common in situ carcinoma of the skin.Areas covered: In this article, we cover the established algorithm of treating AK and give an insight into the drugs under development. There are six compounds under development covering different treatment angles, from Sinecatechin a Polyphenon E which targets the link between HPV infection and development of AK, over Tirbanibulin which targets the SRC proto-oncogene and fast proliferating cells, to Tuvatexib a small-molecule dual VDAC/HK2 modulator that has shown that it can compete with the established therapies.Expert opinion: These new treatment options are moving us further toward a more individually tailored treatment for each patient considering his abilities, the size and location of his lesions but also the genetic bases as well as individual risk of transforming into a iSCC and possibly other factors contributing to each patients individual AK lesions.
| Errataetall: |
CommentIn: Expert Opin Emerg Drugs. 2021 Dec;26(4):433-434. - PMID 34749552 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 25(2020), 1 vom: 18. März, Seite 49-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cramer, Philipp [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.02.2021 Date Revised 24.01.2022 published: Print-Electronic CommentIn: Expert Opin Emerg Drugs. 2021 Dec;26(4):433-434. - PMID 34749552 Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2020.1730810 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306615568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306615568 | ||
| 003 | DE-627 | ||
| 005 | 20231225123749.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2020.1730810 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306615568 | ||
| 035 | |a (NLM)32067498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cramer, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Actinic keratosis |b where do we stand and where is the future going to take us? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2021 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Expert Opin Emerg Drugs. 2021 Dec;26(4):433-434. - PMID 34749552 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Actinic keratosis (AK) is a chronic disease which is mainly located across areas of sun-exposed skin. Clinical and subclinical lesions coexist across a large area resulting in a field cancerization. As these lesions have the potential to transform into invasive squamous cell carcinoma (iSCC), treatment is crucial. With global prevalence increasing, AK is expected to be the most common in situ carcinoma of the skin.Areas covered: In this article, we cover the established algorithm of treating AK and give an insight into the drugs under development. There are six compounds under development covering different treatment angles, from Sinecatechin a Polyphenon E which targets the link between HPV infection and development of AK, over Tirbanibulin which targets the SRC proto-oncogene and fast proliferating cells, to Tuvatexib a small-molecule dual VDAC/HK2 modulator that has shown that it can compete with the established therapies.Expert opinion: These new treatment options are moving us further toward a more individually tailored treatment for each patient considering his abilities, the size and location of his lesions but also the genetic bases as well as individual risk of transforming into a iSCC and possibly other factors contributing to each patients individual AK lesions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 5-fuorouracil | |
| 650 | 4 | |a Actinic keratosis | |
| 650 | 4 | |a Diclofenac | |
| 650 | 4 | |a Furosemide and Digoxin | |
| 650 | 4 | |a Imiquimod | |
| 650 | 4 | |a Ingenol Mebutate | |
| 650 | 4 | |a Paclitaxel | |
| 650 | 4 | |a SRC proto-oncogene | |
| 650 | 4 | |a Tirbanibulin | |
| 650 | 4 | |a Tuvatexib | |
| 650 | 4 | |a VDAC/HK2 modulator | |
| 650 | 4 | |a cryotherapy | |
| 650 | 4 | |a photodynamic therapy | |
| 650 | 4 | |a polyphenon E | |
| 650 | 4 | |a potassium dobesilate | |
| 650 | 4 | |a squamous cell carcinoma | |
| 650 | 4 | |a tubulin beta class I | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a MAS1 protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Mas |2 NLM | |
| 650 | 7 | |a Voltage-Dependent Anion Channels |2 NLM | |
| 650 | 7 | |a Catechin |2 NLM | |
| 650 | 7 | |a 8R1V1STN48 |2 NLM | |
| 650 | 7 | |a Hexokinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a polyphenon E |2 NLM | |
| 650 | 7 | |a T432289GYZ |2 NLM | |
| 700 | 1 | |a Stockfleth, Eggert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 25(2020), 1 vom: 18. März, Seite 49-58 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:1 |g day:18 |g month:03 |g pages:49-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2020.1730810 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 1 |b 18 |c 03 |h 49-58 | ||